Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Lancet Child Adolesc Health 9:297305 Argente J, Verge CF, Okorie U et al (2025) Setmelanotide in patients aged 25 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial
These could lead to dehydration and potentially acute kidney injury
This dual benefit of blood sugar regulation and weight loss makes GLP-1 agonists a particularly attractive option for patients who struggle with both diabetes and obesity
The SURPASS-2 trial showed Mounjaro 15 mg produced nearly twice the weight loss of Ozempic 1 mg in people with type 2 diabetes
US$ 20.77
US$ 25.74
US$ 21.62
